I have a 24-month-old patient with HIV infection and I want to use the quadrivalent meningococcal conjugate brand Menactra (MenACWY-D) because this is the only vaccine we have available in our clinic. However, this child received DTaP vaccine yesterday at another clinic. Can I administer MenACWY-D?

If Menactra (MenACWY-D) is to be administered to a child at increased risk for meningococcal disease, including children who have HIV infection, Menactra should be given either before, at the same visit, or at least 6 months after DTaP. This is because data suggest a reduced response to the Menactra if given within a month after DTaP. Menactra may be used earlier than 6 months after DTaP if it is the only available option and vaccination is necessary due to travel to an area with epidemic or hyperendemic meningococcal disease. Menveo (MenACWY-CRM) and MenQuadfi (MenACWY-TT) vaccines may be given at any time before or after DTaP.